

Caicun Zhou

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2908857/publications.pdf>

Version: 2024-02-01

38
papers

16,469
citations

236612

25
h-index

315357

38
g-index

38
all docs

38
docs citations

38
times ranked

12976
citing authors

#	ARTICLE	IF	CITATIONS
1	Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. <i>Lancet Oncology</i> , The, 2011, 12, 735-742.	5.1	3,758
2	Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2018, 378, 113-125.	13.9	3,530
3	Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. <i>Lancet</i> , The, 2019, 393, 1819-1830.	6.3	2,347
4	Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 213-222.	5.1	1,740
5	Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. <i>New England Journal of Medicine</i> , 2020, 382, 41-50.	13.9	1,725
6	Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. <i>Lancet Oncology</i> , The, 2015, 16, 141-151.	5.1	1,369
7	BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 2197-2204.	0.8	323
8	Tumor neoantigens: from basic research to clinical applications. <i>Journal of Hematology and Oncology</i> , 2019, 12, 93.	6.9	266
9	Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12). <i>Journal of Thoracic Oncology</i> , 2021, 16, 1501-1511.	0.5	158
10	EGFR TKIs plus WBRT Demonstrated No Survival Benefit Other Than That of TKIs Alone in Patients with NSCLC and EGFR Mutation and Brain Metastases. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1718-1728.	0.5	118
11	High Discrepancy of Driver Mutations in Patients with NSCLC and Synchronous Multiple Lung Ground-Glass Nodules. <i>Journal of Thoracic Oncology</i> , 2015, 10, 778-783.	0.5	116
12	The Bim deletion polymorphism clinical profile and its relation with tyrosine kinase inhibitor resistance in Chinese patients with non-small cell lung cancer. <i>Cancer</i> , 2014, 120, 2299-2307.	2.0	84
13	Genomic landscape and its correlations with tumor mutational burden, PD-L1 expression, and immune cells infiltration in Chinese lung squamous cell carcinoma. <i>Journal of Hematology and Oncology</i> , 2019, 12, 75.	6.9	84
14	T790M mutation is associated with better efficacy of treatment beyond progression with EGFR-TKI in advanced NSCLC patients. <i>Lung Cancer</i> , 2014, 84, 295-300.	0.9	81
15	Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC: Dusk or Dawn?. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1267-1288.	0.5	77
16	Clinical value of neutrophil-to-lymphocyte ratio in patients with non-small-cell lung cancer treated with PD-1/PD-L1 inhibitors. <i>Lung Cancer</i> , 2019, 130, 76-83.	0.9	73
17	Pretreatment neutrophil-to-lymphocyte ratio is associated with outcome of advanced-stage cancer patients treated with immunotherapy: a meta-analysis. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 713-727.	2.0	68
18	Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer. <i>Cancer</i> , 2019, 125, 1038-1049.	2.0	66

#	ARTICLE	IF	CITATIONS
19	MiR-200c overexpression is associated with better efficacy of EGFR-TKIs in non-small cell lung cancer patients with EGFR wild-type. <i>Oncotarget</i> , 2014, 5, 7902-7916.	0.8	57
20	Prognostic value of PD-L1 expression in combination with CD8 ⁺ TILs density in patients with surgically resected non-small cell lung cancer. <i>Cancer Medicine</i> , 2018, 7, 32-45.	1.3	48
21	Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC: a multicenter phase-II trial. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 355.	7.1	45
22	EGFR-TKIs plus bevacizumab demonstrated survival benefit than EGFR-TKIs alone in patients with EGFR-mutant NSCLC and multiple brain metastases. <i>European Journal of Cancer</i> , 2019, 121, 98-108.	1.3	39
23	The past, present and future of immunotherapy against tumor. <i>Translational Lung Cancer Research</i> , 2015, 4, 253-64.	1.3	34
24	Characterization of Liver Metastasis and Its Effect on Targeted Therapy in EGFR-mutant NSCLC: A Multicenter Study. <i>Clinical Lung Cancer</i> , 2017, 18, 631-639.e2.	1.1	31
25	EGFR-TKIs plus local therapy demonstrated survival benefit than EGFR-TKIs alone in EGFR-mutant NSCLC patients with oligometastatic or oligoprogressive liver metastases. <i>International Journal of Cancer</i> , 2019, 144, 2605-2612.	2.3	30
26	On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trial. <i>Molecular Cancer</i> , 2022, 21, 4.	7.9	28
27	Uncommon EGFR mutations in a cohort of Chinese NSCLC patients and outcomes of first-line EGFR-TKIs and platinum-based chemotherapy. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2017, 29, 543-552.	0.7	27
28	Mutational Landscape of cfDNA Identifies Distinct Molecular Features Associated With Therapeutic Response to First-Line Platinum-Based Doublet Chemotherapy in Patients with Advanced NSCLC. <i>Theranostics</i> , 2017, 7, 4753-4762.	4.6	25
29	Characterization of PD-L1 protein expression and CD8 ⁺ tumor-infiltrating lymphocyte density, and their associations with clinical outcome in small-cell lung cancer. <i>Translational Lung Cancer Research</i> , 2019, 8, 748-759.	1.3	22
30	PD-L1 expression and its effect on clinical outcomes of EGFR-mutant NSCLC patients treated with EGFR-TKIs. <i>Cancer Biology and Medicine</i> , 2018, 15, 434.	1.4	19
31	Synchronous ground-glass nodules showed limited response to anti-PD-L1/PD-L1 therapy in patients with advanced lung adenocarcinoma. <i>Clinical and Translational Medicine</i> , 2020, 10, e149.	1.7	18
32	Heterogeneity of neoantigen landscape between primary lesions and their matched metastases in lung cancer. <i>Translational Lung Cancer Research</i> , 2020, 9, 246-256.	1.3	17
33	Combination immune checkpoint inhibitors with platinum-based chemotherapy in advanced non-small cell lung cancer: what's known and what's next. <i>Translational Lung Cancer Research</i> , 2019, 8, S447-S450.	1.3	12
34	Characterization of evolution trajectory and immune profiling of brain metastasis in lung adenocarcinoma. <i>Npj Precision Oncology</i> , 2021, 5, 6.	2.3	12
35	China experts consensus on icotinib for non-small cell lung cancer treatment (2015 version). <i>Annals of Translational Medicine</i> , 2015, 3, 260.	0.7	9
36	China experts consensus on icotinib for non-small cell lung cancer treatment (2015 version). <i>Journal of Thoracic Disease</i> , 2015, 7, E468-72.	0.6	6

#	ARTICLE	IF	CITATIONS
37	Does selected immunological panel possess the value of predicting the prognosis of early-stage resectable non-small cell lung cancer?. <i>Translational Lung Cancer Research</i> , 2019, 8, 559-574.	1.3	5
38	Chinese expert consensus on molecularly targeted therapy for advanced non-small cell lung cancer (2013 edition). <i>Journal of Thoracic Disease</i> , 2014, 6, 1489-98.	0.6	2